ATG5 and neoplasm: In vivo, co-administration of the sh-RPS6KA2 plasmid and cisplatin significantly increased the expression of ATG5, ATG7, and BECN1, as well as promoted subcutaneous tumor growth compared to cisplatin monotherapy (Fig. 8A).